Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / FZD10

FZD10

Basics

Aliases:
This biomarker is also known as:
  • CD350,
  • Fz10,
  • Q9ULW2,
  • FZ-10,
  • frizzled (Drosophila) homolog 10,
  • hFz10,
  • frizzled 10, seven transmembrane spanning receptor,
  • frizzled-10,
  • frizzled homolog 10 (Drosophila),
  • frizzled homolog 10,
  • FzE7,
  • frizzled family receptor 10,
  • Fz-10,
  • CD350 antigen,

View in BioMuta

Description…

FZD10 is a member of the frizzled gene family. The frizzled gene family encodes 7-transmembrane domain proteins that are receptors for the Wingless type MMTV integration site family of signaling proteins (WNT signaling proteins). The highest levels of expression for FZD10 are seen in the placenta and fetal kidney, followed by fetal lung and brain. Using array analysis, expression of this intronless gene is significantly up-regulated in two cases of primary colon cancer.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: FZD10

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

FZD10 may be considered for further preclinical testing as a tumor biomarker.

Performance Comment

FZD10 was overexpressed in ovarian cancer relative to normal ovary and relative to a panel of normal organs. FZD10 was detected in vascular structures by in situ hybridization in five independent ovarian cancer samples. FZD10 was found in small and larger blood vessels. FZD10 showed limited or no expression by qRT-PCR in normal tissues.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.